First US trial of bone-marrow Stem Cells for heart attack patients proves safe - EurekaAlert! (article link)
- Parent Category: News
17 Sep 2010
- Published: 17 September 2010
The first randomized, placebo-controlled U.S. clinical trial to assess the use of bone marrow-derived mononuclear cells (BMC) in patients after a ST-elevation myocardial infarction (STEMI; severe heart attack) demonstrated a strong safety profile for this cell therapy, based on phase 1 results published in the September issue of the American Heart Journal.
- "The use of adult stem cells, derived from the patient's own bone marrow, presents a potential new type of therapy to benefit individuals after they suffer a heart attack,"
- "Also, these types of stem cells do not possess any of the ethical concerns of embryonic stem cell research."
First US trial of bone-marrow stem cells for heart attack patients proves safe